Table 1 Clinical characteristics of reports on antineoplastic drugs and vitiligo collected from the FAERS database between January 2004 and June 2024.
From: Real world pharmacovigilance study of antineoplastic drug related vitiligo risks
Characteristics | Case number | Case proportion |
|---|---|---|
Number of events | 553 | |
Sex | ||
F | 246 | 44.5% |
M | 225 | 40.7% |
Missing | 82 | 14.8% |
Weight(kg) | ||
< 50 | 5 | 0.9% |
> 100 | 6 | 1.1% |
50 ~ 100 | 86 | 15.6% |
Missing | 456 | 82.5% |
Age(year) | ||
< 18 | 6 | 1.1% |
> 85 | 7 | 1.3% |
18–65 | 232 | 42.0% |
66–85 | 134 | 24.2% |
Missing | 174 | 31.5% |
Reporting Personnel | ||
Consumer | 117 | 21.2% |
Health Professional | 124 | 22.4% |
Physician | 212 | 38.3% |
Other health-professional | 78 | 14.1% |
Pharmacist | 17 | 3.1% |
Missing | 5 | 0.9% |
Reported Countries (top five) | ||
United States | 204 | 36.9% |
France | 70 | 12.7% |
Germany | 34 | 6.1% |
Spain | 19 | 3.4% |
Japan | 18 | 3.3% |
Indications (top five) | ||
Malignant melanoma | 143 | 25.9% |
Metastatic malignant melanoma | 130 | 23.5% |
Breast cancer | 19 | 3.4% |
Breast cancer metastatic | 18 | 3.3% |
Non-small cell lung cancer | 15 | 2.7% |
Time to event onset (days) | ||
0–30 days | 23 | 4.2% |
31–60 days | 13 | 2.4% |
61–90 days | 9 | 1.6% |
91–180 days | 17 | 3.1% |
181–360 days | 16 | 2.9% |
> 360 days | 16 | 2.9% |
Death or life-threatening outcome | ||
Pembrolizumab | 14 | 2.5% |
Nivolumab | 13 | 2.4% |
Ipilimumab | 4 | 0.7% |
Atezolizumab | 3 | 0.5% |
Trametinib | 2 | 0.4% |
Dabrafenib | 1 | 0.2% |
Cyclophosphamide | 1 | 0.2% |
Capecitabine | 1 | 0.2% |
Bevacizumab | 1 | 0.2% |
